These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 16344278)
1. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Twelves C; Gollins S; Grieve R; Samuel L Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278 [TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Ward S; Kaltenthaler E; Cowan J; Brewer N Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K; Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435 [TBL] [Abstract][Full Text] [Related]
4. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800 [TBL] [Abstract][Full Text] [Related]
5. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Pfeiffer P; Mortensen JP; Bjerregaard B; Eckhoff L; Schønnemann K; Sandberg E; Aabo K; Jakobsen A Eur J Cancer; 2006 Nov; 42(16):2738-43. PubMed ID: 17011184 [TBL] [Abstract][Full Text] [Related]
6. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138 [TBL] [Abstract][Full Text] [Related]
7. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P; J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577 [TBL] [Abstract][Full Text] [Related]
9. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199 [TBL] [Abstract][Full Text] [Related]
10. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C; Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678 [TBL] [Abstract][Full Text] [Related]
11. On prejudice and facts and choices. Köhne CH; Folprecht G Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244 [No Abstract] [Full Text] [Related]
12. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156 [TBL] [Abstract][Full Text] [Related]
13. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667 [TBL] [Abstract][Full Text] [Related]
15. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. Comella P; Massidda B; Filippelli G; Farris A; Natale D; Barberis G; Maiorino L; Palmeri S; Cannone M; Condemi G; J Cancer Res Clin Oncol; 2009 Feb; 135(2):217-26. PubMed ID: 18719941 [TBL] [Abstract][Full Text] [Related]
16. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Hoff PM; Ansari R; Batist G; Cox J; Kocha W; Kuperminc M; Maroun J; Walde D; Weaver C; Harrison E; Burger HU; Osterwalder B; Wong AO; Wong R J Clin Oncol; 2001 Apr; 19(8):2282-92. PubMed ID: 11304782 [TBL] [Abstract][Full Text] [Related]
17. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Saif MW Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249 [TBL] [Abstract][Full Text] [Related]
18. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? Twelves CJ; Cassidy J Br J Cancer; 2002 Jun; 86(11):1670-6. PubMed ID: 12087448 [TBL] [Abstract][Full Text] [Related]
19. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200 [TBL] [Abstract][Full Text] [Related]
20. The evolution of fluoropyrimidine therapy: from intravenous to oral. Hoff PM; Cassidy J; Schmoll HJ Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]